RecombiMAb anti-mouse VEGFR-2抗體

更新時間：2023-10-31 點擊次數(shù)：742次

產(chǎn)品描述：

DC101-CP132單克隆抗體是原始DC101單克隆的重組嵌合型抗體。可變結(jié)構(gòu)域序列與原始DC101相同，但是恒定區(qū)序列已經(jīng)從大鼠IgG1變?yōu)樾∈驣gG2a。DC101-CP132單克隆抗體像原始大鼠IgG1抗體一樣，不包含F(xiàn)c突變。

DC101-CP132單克隆抗體能與小鼠VEGFR-2(血管內(nèi)皮生長因子受體2)反應(yīng)，VEGFR-2也稱為CD309、KDR和Flk-1。VEGFR-2是酪氨酸蛋白激酶家族的成員。當(dāng)結(jié)合到其配體血管內(nèi)皮生長因子時發(fā)揮生理作用，血管內(nèi)皮生長因子受體-2在血管發(fā)育和通透性中起關(guān)鍵作用。血管內(nèi)皮生長因子受體-2在成人心臟、肺、腎、腦和骨骼肌的內(nèi)皮細(xì)胞中高表達(dá)，在其他組織中低表達(dá)。DC101單克隆抗體已被證明在體內(nèi)抑制VEGFR-2信號傳導(dǎo)。

BioXCell熱銷產(chǎn)品--RecombiMAb anti-mouse VEGFR-2

產(chǎn)品詳情：

產(chǎn)品名稱	RecombiMAb anti-mouse VEGFR-2
產(chǎn)品貨號	CP132
產(chǎn)品規(guī)格	1/5/25/50/100mg
反應(yīng)種屬	Mouse
克隆號	DC101-CP132
同種型	Mouse IgG2a(switched from rat IgG1)
免疫原	Mouse VEGFR-2-SEAPs soluble receptor
實驗應(yīng)用	in vivo blocking of VEGF/VEGFR-2 signaling* in vitro blocking of VEGFR signaling* Western blot* *Reported for the original rat IgG1 DC101 antibody
產(chǎn)品形式	PBS, pH 7.0,Contains no stabilizers or preservatives
純度	>95%, Determined by SDS-PAGE
聚合	<5%, Determined by SEC
無菌處理	0.2 µm filtration
純化方式	Protein G
分子量	150 kDa
小鼠病原檢測	Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative
保存條件	抗體原液保存在4°C，不能冷凍保存。
推薦同型對照	InVivoPlus mouse IgG2a isotype control, unknown specificity（貨號BP0085）
推薦抗體稀釋液	InVivoPure pH 7.0 Dilution Buffer（貨號IP0070）

該產(chǎn)品自上市已被多篇SCI文獻(xiàn)引用，品質(zhì)有保證，以下是部分已發(fā)表的文獻(xiàn)引用：

應(yīng)用

文章

體內(nèi)VEGF/VEGFR-2信號阻斷

(in vivo blocking of VEGF/VEGFR-2 signaling)

1. Ding, X., et al. (2015). 'Distinct functions of epidermal and myeloid-derived VEGF-A in skin tumorigenesis mediated by HPV8' Cancer Res 75(2): 330-343.

2. Lee, H. J., et al. (2015). 'Inhibition of vascular endothelial growth factor A and hypoxia-inducible factor 1alpha maximizes the effects of radiation in sarcoma mouse models through destruction of tumor vasculature' Int J Radiat Oncol Biol Phys 91(3): 621-630.

3. Arulanandam, R., et al. (2015). 'VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection' Cancer Cell 28(2): 210-224.

4. Kizhatil, K., et al. (2014). 'Schlemm’s canal is a unique vessel with a combination of blood vascular and lymphatic phenotypes that forms by a novel developmental process' PLoS Biol 12(7): e1001912.

體內(nèi)VEGF/VEGFR-2信號阻斷，體外VEGFR信號阻斷

(in vivo blocking of VEGF/VEGFR-2 signaling, in vitro blocking of VEGFR signaling)

1.Larrayoz, M., et al. (2014). 'Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype' EMBO Mol Med 6(4): 539-550.

更多產(chǎn)品詳情請聯(lián)系 BioXCell 中國授權(quán)代理——欣博盛生物

上一篇：BioXCell產(chǎn)品介紹--RecombiMAb anti-mouse PD-L1 (B7-H1) (D265A)

下一篇：高分文獻(xiàn)解讀｜慢性肺部感染促進(jìn)乳腺癌肺轉(zhuǎn)移新機(jī)制

返回列表>>

13129540117